Funding for this research was provided by:
Kaiser Permanente Southern California
Article History
Received: 29 November 2022
Revised: 15 June 2023
Accepted: 6 July 2023
First Online: 25 July 2023
Declarations
:
: This study was approved by the KPSC institutional review board, which waived the requirement for informed consent.
: TBC received research funding from GlaxoSmithKline (GSK) group of companies for other studies outside of the submitted work. BKA received research funding from the GSK group of companies, Novavax, Seqirus, Dynavax, Moderna, Pfizer, and Genentech for other studies outside of the submitted work. HFT received research funding from the GSK group of companies and Moderna for other studies outside of the submitted work.